Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 12/20 | 0.49 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.43 |
| ▸ | MTOR | P42345 | 6/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780760 | 1.00 | ATR (0.49) | ATRATRIPPIK3CAMTORPIK3CD | |
| SCHEMBL29678436 | 1.00 | ATR (0.49) | ATRATRIPPIK3CAMTORPIK3CD | |
| SCHEMBL23780757 | 0.90 | ATR (0.48) | ATRATRIPPIK3CAMTORPIK3CD | |
| SCHEMBL29678463 | 0.90 | ATR (0.48) | ATRATRIPPIK3CAMTORPIK3CD | |
| SCHEMBL23780755 | 0.90 | ATR (0.48) | ATRATRIPPIK3CAMTORPIK3CD | |
| SCHEMBL23780781 | 0.88 | ATR (0.51) | ATRATRIPMTOR | |
| SCHEMBL23780779 | 0.88 | ATR (0.51) | ATRATRIPMTOR | |
| SCHEMBL23780784 | 0.88 | ATR (0.51) | ATRATRIPPIK3CAMTOR | |
| SCHEMBL23780785 | 0.88 | ATR (0.51) | ATRATRIPPIK3CAMTOR | |
| SCHEMBL29678485 | 0.88 | ATR (0.51) | ATRATRIPMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | ATR 1/4885ATRIP 11/4885PIK3CA 126/4885 |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | ATR 1/4885ATRIP 5/4885PIK3CA 402/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | ATR 1/4885ATRIP 11/4885PIK3CA 126/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | ATR 1/4885ATRIP 11/4885PIK3CA 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.